facebook button Ipsen RESILIENT: Second Line Irinotecan Versus Topotecan
Español  |  中國傳統的  |  简体中文
Call us  (855) 528-7322
Main Menu

Ipsen RESILIENT: Second Line Irinotecan Versus Topotecan

Sponsor: IPSEN Bioscience, Inc.

A randomized, phase 3 trial of irinotecan liposomal injection versus topotecan in small cell lung cancer patients that have previously progressed after being treated with first line platinum-based chemotherapy.

For more information please contact the clinical research department: 631-675-5075